Liquid biopsy for children with central nervous system tumours: Clinical integration and technical considerations.
Loading...
Embargo End Date
ICR Authors
Authors
Stankunaite, R
Marshall, LV
Carceller, F
Chesler, L
Hubank, M
George, SL
Marshall, LV
Carceller, F
Chesler, L
Hubank, M
George, SL
Document Type
Journal Article
Date
2022-11-16
Date Accepted
2022-10-28
Abstract
Circulating cell-free DNA (cfDNA) analysis has the potential to revolutionise the care of patients with cancer and is already moving towards standard of care in some adult malignancies. Evidence for the utility of cfDNA analysis in paediatric cancer patients is also accumulating. In this review we discuss the limitations of blood-based assays in patients with brain tumours and describe the evidence supporting cerebrospinal fluid (CSF) cfDNA analysis. We make recommendations for CSF cfDNA processing to aid the standardisation and technical validation of future assays. We discuss the considerations for interpretation of cfDNA analysis and highlight promising future directions. Overall, cfDNA profiling shows great potential as an adjunct to the analysis of biopsy tissue in paediatric cancer patients, with the potential to provide a genetic molecular profile of the tumour when tissue biopsy is not feasible. However, to fully realise the potential of cfDNA analysis for children with brain tumours larger prospective studies incorporating serial CSF sampling are required.
Citation
Frontiers in Pediatrics, 2022, 10 pp. 957944 -
Source Title
Frontiers in Pediatrics
Publisher
FRONTIERS MEDIA SA
ISSN
2296-2360
eISSN
2296-2360
2296-2360
2296-2360
Collections
Research Team
Paediatric Tumour Biology
Developmental Oncology
Developmental Oncology